These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1119 related articles for article (PubMed ID: 27974412)

  • 1. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.
    Wong D; Nielsen TB; Bonomo RA; Pantapalangkoor P; Luna B; Spellberg B
    Clin Microbiol Rev; 2017 Jan; 30(1):409-447. PubMed ID: 27974412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acinetobacter: microbiological, pathogenetic and resistant properties].
    Chebotar IV; Lazareva AV; Masalov YK; Mikhailovich VM; Mayanskiy NA
    Vestn Ross Akad Med Nauk; 2014; (9-10):39-50. PubMed ID: 25816642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-acquired bloodstream infections caused by Acinetobacter baumannii: A matched case-control study.
    Chen CT; Wang YC; Kuo SC; Shih FH; Chen TL; How CK; Yang YS; Lee YT
    J Microbiol Immunol Infect; 2018 Oct; 51(5):629-635. PubMed ID: 28701266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acinetobacter baumannii: an emerging multidrug-resistant threat.
    Gootz TD; Marra A
    Expert Rev Anti Infect Ther; 2008 Jun; 6(3):309-25. PubMed ID: 18588496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Acinetobacter infections.
    Michalopoulos A; Falagas ME
    Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.
    Shi J; Sun T; Cui Y; Wang C; Wang F; Zhou Y; Miao H; Shan Y; Zhang Y
    BMC Infect Dis; 2020 Aug; 20(1):597. PubMed ID: 32787942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First report of cavitary pneumonia due to community-acquired Acinetobacter pittii, study of virulence and overview of pathogenesis and treatment.
    Larcher R; Pantel A; Arnaud E; Sotto A; Lavigne JP
    BMC Infect Dis; 2017 Jul; 17(1):477. PubMed ID: 28683724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-resistant Acinetobacter: a threat to the antibiotic era.
    Peleg AY; Paterson DL
    Intern Med J; 2006 Aug; 36(8):479-82. PubMed ID: 16866649
    [No Abstract]   [Full Text] [Related]  

  • 9. Emergence of antimicrobial resistance among Acinetobacter species: a global threat.
    Clark NM; Zhanel GG; Lynch JP
    Curr Opin Crit Care; 2016 Oct; 22(5):491-9. PubMed ID: 27552304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Resistance in
    Lupo A; Haenni M; Madec JY
    Microbiol Spectr; 2018 Jun; 6(3):. PubMed ID: 30101740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview.
    Doughari HJ; Ndakidemi PA; Human IS; Benade S
    Microbes Environ; 2011; 26(2):101-12. PubMed ID: 21502736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibiotic resistance patterns in Acinetobacter spp. strains isolated from hospital environment].
    Văduva DB; Muntean D; Lonescu G; Licker M; Văduva MB; Velimirovici D; Rădulescu M; Dumitraşcu V; Crăciunescu M; Dugăeşescu D; Horhat F; Piluţ C; Bădiţoiu L; Moldovan R
    Bacteriol Virusol Parazitol Epidemiol; 2008; 53(2):103-7. PubMed ID: 19856849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases.
    Özvatan T; Akalın H; Sınırtaş M; Ocakoğlu G; Yılmaz E; Heper Y; Kelebek N; İşçimen R; Kahveci F
    Respirology; 2016 Feb; 21(2):363-9. PubMed ID: 26635315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
    Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
    Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
    Jain R; Danziger LH
    Ann Pharmacother; 2004 Sep; 38(9):1449-59. PubMed ID: 15280512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.
    Kempf M; Rolain JM
    Int J Antimicrob Agents; 2012 Feb; 39(2):105-14. PubMed ID: 22113193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter.
    Espinal P; Roca I; Vila J
    Future Microbiol; 2011 May; 6(5):495-511. PubMed ID: 21585259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibiotic resistance of Acinetobacter baumannii strains isolated from clinical specimens in the "Marius Nasta" Pneumology Institute, Bucharest].
    Moisoiu A; Ionită M; Sârbu L; Stoica C; Grigoriu L
    Pneumologia; 2014; 63(2):109-11. PubMed ID: 25241558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options for Acinetobacter baumannii infections.
    Vila J; Pachón J
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug treatment for multidrug-resistant Acinetobacter baumannii infections.
    Bassetti M; Righi E; Esposito S; Petrosillo N; Nicolini L
    Future Microbiol; 2008 Dec; 3(6):649-60. PubMed ID: 19072182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.